Elimination and degradation of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with end-stage renal disease by Idorn, Thomas et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Elimination and degradation of glucagon-like peptide-1 and glucose-dependent
insulinotropic polypeptide in patients with end-stage renal disease
Idorn, Thomas; Knop, Filip K; Jørgensen, Morten B; Christensen, Mikkel; Holst, Jens Juul;
Hornum, Mads; Feldt-Rasmussen, Bo
Published in:
The Journal of clinical endocrinology and metabolism
DOI:
10.1210/jc.2013-3809
Publication date:
2014
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
Idorn, T., Knop, F. K., Jørgensen, M. B., Christensen, M., Holst, J. J., Hornum, M., & Feldt-Rasmussen, B.
(2014). Elimination and degradation of glucagon-like peptide-1 and glucose-dependent insulinotropic
polypeptide in patients with end-stage renal disease. The Journal of clinical endocrinology and metabolism,
99(7), 2457-66. [jc20133809]. https://doi.org/10.1210/jc.2013-3809
Download date: 03. Feb. 2020
Elimination and Degradation of Glucagon-like
Peptide-1 and Glucose-Dependent Insulinotropic
Polypeptide in Patients with End-Stage Renal Disease
Thomas Idorn, Filip K. Knop, Morten B. Jørgensen, Mikkel Christensen,
Jens J. Holst, Mads Hornum, and Bo Feldt-Rasmussen
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M.C.), Gentofte Hospital, University of Copenhagen, DK-2900 Hellerup, Denmark; and The NNF Center
for Basic Metabolic Research, Department of Biomedical Sciences (F.K.K., J.J.H.), the Panum Institute,
University of Copenhagen, DK-2200 Copenhagen, Denmark
Context: The affect of the kidneys in elimination and degradation of intact incretin hormones and
their truncated metabolites is unclear.
Objective: To evaluate elimination and degradation of glucose-dependent insulinotropic poly-
peptide (GIP) and glucagon-like peptide-1 (GLP-1) in patients with dialysis-dependent kidney
failure.
SettingandDesign:Twelvenon-diabetic patients treatedwith chronic hemodialysis and12 control
subjects were examined in a double-blind, randomized, matched observational study at the De-
partment of Nephrology, Rigshospitalet, University of Copenhagen, Denmark. Over 4 separate
study days, synthetic human GIP or GLP-1 was infused with or without concurrent inhibition of
dipeptidyl peptidase 4 using sitagliptin or placebo. Plasma concentrations of glucose, insulin,
glucagon, and intact and total forms of GLP-1 or GIP were measured repeatedly. Plasma half-life
(T1/2), metabolic clearance rate (MCR), area under curve, and volume of distribution for intact and
metabolite levels of GLP-1 and GIP were calculated.
Results: Fasting concentrations of intactGLP-1 andGIPwere increased indialysis patients (P .001)
whereas fasting levels ofGLP-1 andGIPmetabolites didnotdiffer betweengroups (P .738).MCRs
of intact GLP-1 andGIP, and the GLP-1metabolitewere reduced in dialysis patients on the placebo
day (P .009), and T1/2 of intact andmetabolite forms of GLP-1 andGIPwere comparable between
groups (P  .121).
Conclusions: Unexpectedly, degradation and elimination of the intact and metabolite forms of
GLP-1 and GIP seemed preserved, although reduced, in patients with dialysis-dependent kidney
failure. (J Clin Endocrinol Metab 99: 2457—2466, 2014)
The kidneys are involved in elimination and degrada-tionof anumberofhormones anddrugs.The incretin
hormones, glucagon-like peptide-1 (GLP-1) and glucose-
dependent insulinotropic polypeptide (GIP), are secreted
from enteroendocrine L and K cells, respectively, in re-
sponse to food ingestion. They stimulate insulin secretion
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and regulate glucagon secretion in a glucose-dependent
manner (1, 2). It is widely accepted that the intact forms of
the incretin hormones, GLP-1(7–36) amide and GIP(1–
42), are degraded primarily by the ubiquitous enzyme di-
peptidyl peptidase 4 (DPP-4) (3–5) and to a minor extent
by various neutral endopeptidases (NEPs) and additional
aminopeptidases (6–8). DPP-4 cleaves off the N-terminal
dipeptide of both incretin hormones yielding inactive me-
tabolites, GIP(3–42) and GLP-1(9–36) amide, respec-
tively. These metabolites are believed primarily to be re-
nally cleared (3–5, 9–13), although other mechanisms
may contribute, including extraction in peripheral tissues
(9, 14). Only a few studies have examined the effect of
impaired kidney function on elimination and degradation
of the incretin hormones (10–12, 15–17). Most of these
studies were performed in vitro or using animal models
and most were based on assays unable to distinguish be-
tween intact hormones and metabolites. Recent studies
from our group have suggested a preserved ability to elim-
inate GLP-1 and GIP in patients with severely reduced
kidney function, although only the total forms of the in-
cretin hormones were examined (18, 19). In the present
study we determined degradation and elimination of in-
tact forms and truncatedmetabolites of GLP-1 andGIP in
patients with chronic dialysis-dependent, end-stage renal
disease (ESRD), ie patients with no or severely reduced
kidney function. We hypothesized that patients with
ESRD would be characterized by severe disturbances in
the metabolism of both intact and, in particular, metab-
olite forms of the incretin hormones, caused by reduced
renal function and uremia per se.
Materials and Methods
Study protocol
The study protocol was approved by the Scientific-Ethical Com-
mittee of theCapital Region ofDenmark (H-2-2009-158) and by the
Danish Data Protection Agency (2007-58-0015). The study was reg-
isteredwithclinicaltrials.gov(NCT01391884).Writteninformedcon-
sentwasobtainedand the studywas conductedaccording to the latest
revision of the Helsinki Declaration.
Subjects
We included 12 patients with ESRD (9 Caucasians, 2 Asians,
and 1 African American) and 12 control subjects with normal
kidney function (all Caucasians). Patients were recruited from
the hemodialysis clinic at the Department of Nephrology, Rig-
shospitalet, Denmark. Control subjects were recruited among
participants from previous projects (18, 19). Patients were
matched with the control subjects according to age, sex, and
body mass index (BMI). Inclusion criteria were age 18–90 y,
chronic hemodialysis treatment (for3months), andBMI18.5–
28.0kg/m2. Patientswithdiabetes, pancreatitis, bowel resection,
inflammatory bowel disease, malignancy (previous or present),
daily intake of medication known to influence glucose metabo-
lism, or severe anemia were excluded. Control subjects met the
same exclusionand inclusion criteria apart fromhaving anormal
kidney function (evaluated from plasma creatinine). Underlying
renal diagnoses in the ESRD group included polycystic kidney
disease (N  3), interstitial nephritis (N  2), hypertensive ne-
phropathy (N  2), hemolytic uremic syndrome (N  1), amy-
loidosis (N 1), congenital urinary tract malformation (N 1),
andunknown (N2).Concomitant pharmacological treatment
in the ESRD group included weekly darbepoetin alfa and iron
infusions (N 12), daily use of vitamin substitutions and phos-
phorus binders (N  12), pantoprazole (N  7), furosemide
(N 4) and less frequently used agents (Supplemental Table 1).
Glucose tolerance was assessed at an initial screening visit using
a 2-h 75-g oral glucose tolerance test. One patient with ESRD
had impaired glucose tolerance, 1 control subject had impaired
fasting glucose, and all other participants had normal glucose
tolerance (20). Nine patients with ESRD had well-treated mild-
to-moderate hypertension (defined as use of antihypertensive
agents and/or blood pressure 140/90 mm Hg at the screening
visit), and one control subject had mild hypertension. Antihy-
pertensive treatment in the ESRDgroup includedACE inhibitors
(N 4), angiotensin II receptor antagonists (N 5), beta block-
ers (N 3), and calcium channel blockers (N 2). One control
subject used beta blockers. Two patients with ESRD and one
control subject was mildly overweight (BMI 25 kg/m2). No
participants had clinically significant cardiovascular disease.
Subject characteristics are presented in Table 1.
Hormone infusions, capsules, and blinding
HumanGLP-1(7–36) amideandhumanGIP(1–42)werepur-
chased from PolyPeptide Laboratories. The peptides were dem-
onstrated to be greater than 97% pure and identical to the nat-
ural humanpeptides byHPLC,mass, and sequence analysis. The
peptideswere dissolved in sterilizedwater containing2%human
albumin (Statens Serum Institut) and subjected to duplicate ster-
ile filtration at the Capital Region Pharmacy. Based on the mo-
lecular weights of the peptides (GLP-1(7–36) amide, 3297.67
g/mol; and GIP(1–42), 4983.68 g/mol) (21), the final GLP-1
infusion solution contained 5 g/mL and the GIP infusion solu-
tion contained15g/mL tobe able tokeep theweight-dependent
infusions blinded. Infusion solutions were dispensed into glass
ampoules and stored frozen (20°C). The Capital Region Phar-
macy also delivered blinded gelatin capsules containing 50 mg
sitagliptin or placebo (placebo composed of lactose monohy-
drate, potato starch, gelatin, magnesium stearate, and talc). The
products were delivered blinded with sealed randomization
codes.
Experimental procedures
All participants went through 4 double-blinded examination
days in randomized order: A) GLP-1 infusion  sitagliptin, B)
GLP-1 infusion placebo, C) GIP infusion sitagliptin, andD)
GIP infusion  placebo. One patient underwent kidney trans-
plantation after 3 examination days and, consequently, the
fourth examination daywas not performed (GIP infusion pla-
cebo). All other participants accomplished 4 examination days.
A minimum of 72 h passed between the examination days and
patients were free of dialysis treatment for greater than 36 hours
before examination. Participants were examined after an over-
night fast (10 h), and neither alcohol consumption nor vigorous
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physical activities was permitted 24 h prior to examination. A
cannulawas inserted into a cubital vein for hormone infusion. In
control subjects, an additional iv access (for collection of blood
samples) was established from the contralateral cubital vein us-
ing an iv catheter (gauge 18),whereas blood sampleswere drawn
from an arterio-venous fistula located at the forearm in patients
with ESRD using fistula needles (gauge 17). The arm of the con-
trol subjects with the iv access for blood sampling was wrapped
in a heating pad (50°C) to arterialize the blood. Each participant
ingested 2 capsules containing a total of 100 mg sitagliptin or
placebo 1 h prior to study start (60 minutes). A hormone in-
fusion, consisting of GLP-1(7–36) amide or GIP(1–42) (weight-
dependent and blinded), 10 mL of 5% human albumin (CSL
Behring), filled with isotonic saline (9 g/L; Amgros) to a total of
50 mL, was started at 0 minutes. The hormones were infused in
doses expected to result in postprandial plasma levels (0.5 pmol
GLP-1(7–36) amide/kg body weight/min and 1.0 pmol GIP(1–
42)/kg body weight/min) in accordance with previous studies
(10).The infusionwas completedafter60minutes and succeeded
by a 2-h observational period. Venous blood samples were col-
lected at time15, 0, 20, 40, 60, 62, 64, 66, 70, 80, 90, 120, 150,
and 180 min (frequent sampling immediately following termi-
nation of hormone infusion due to short plasma half-lifes (T1/2)
of both incretinhormones). Bloodwas sampled into chilled tubes
containing EDTA plus a specific DPP-4 inhibitor (valine-pyrro-
lidide; final concentration, 0.01 mmol/L) for analyses of gluca-
gon, GLP-1, and GIP. Tubes were immediately cooled on ice,
centrifuged (1200 g for 20 min at 4°C) and stored frozen
(80°C). For analyses of insulin, bloodwas sampled into chilled
dry tubes and left to coagulate for 30 min at room temperature
before centrifugation. For bedside measurement of plasma glu-
cose, blood was collected in tubes containing sodium fluoride
and centrifuged immediately (7400 g for 2 min at room
temperature).
Analyses
Following completion of all examination days, the study was
unblinded in order to allocate plasma samples from days of
GLP-1 infusion to GLP-1 analysis, and plasma samples from
days of GIP infusion were sent for GIP analysis. Plasma samples
from the days of GLP-1 infusion were assayed for total GLP-1
immunoreactivity using an antiserum that reacts equally with
intact GLP-1 (GLP-1 (7–36) amide) and the N-terminally trun-
cated metabolite (GLP-1 (9–36) amide) (22). Intact GLP-1 was
measured separately using ELISA with two monoclonal anti-
bodies; GLP-1F5 (C-terminally directed) and Mab26.1 (N-ter-
minally directed) (23). Plasma samples from the days of GIP
infusion were assayed for total GIP immunoreactivity using the
C-terminally directed antiserum 867, which reacts fully with
intact GIP (GIP (1–42)) and the metabolite form (GIP (3–42))
(24). Intact GIP immunoreactivity was measured separately us-
ing antiserum no. 98171, which reacts with the N-terminus of
intact GIP (3). Plasma glucose concentrations were measured by
the glucose oxidase method using a glucose analyzer (YSI Inc,
Model 2300 STAT plus, Yellow Springs). Plasma insulin con-
centrations were measured using ELISA kits on a Cobas Fara
robot (Roche Diagnostics GmbH). Glucagon analyses were per-
formed as previously described (25).
Calculations and statistical analyses
Metabolite levels of the incretin hormones were calculated as the
differences between total and intact levels by subtraction (3, 26).Met-
abolicclearancerate(MCR)wascalculatedusingtheformula,MCR
infusion rate/([hormone]plateau  [hormone]basal), where [hormone-
]plateau is the concentrationat 60min, and [hormone]basal is themean
concentration of baseline and 180 min. The fractional clearance
rate, k, was calculated after loge transformation of data by linear
regressionanalysis using the samples collectedafter the endof the
infusion period ( 60 min). T1/2 and the volume of distribution
(Vd) were calculated using standard pharmacokinetic formulas:
T1/2  ln(2)/k and Vd MCR/k. Area under curve (AUC) was
calculated using the trapezoidal rule. Pharmacokinetic datawere
analyzed using GraphPad Prism software, version 6.01. A few
outliers in the calculation of the fractional clearance rate, k,were
detected in both groups by graphical evaluation and removed
prior to further calculations. Fasting concentrations were eval-
uated as mean of the different examination days. Comparisons
of numeric data between groups/examination days were per-
formed using unpaired t test between groups and paired t test
within groups. Fisher’s Exact test was used for comparisons of
categorical data between groups. Responses of plasma glucose,
insulin, and glucagon were evaluated using baseline-subtracted
AUCs. All tests were two-tailed and a P value.05 was consid-
ered significant. Results are expressed asmeans SEMormeans
(95% confidence interval) unless otherwise stated.
Table 1. Demographical and Clinical Data
ESRD Control
P
Valueb
Demographics
Number, N 12 12
Agea, y 44.1  3.1 43.6  3.9 .920
Sex, M/F 8/4 7/5 .673
BMIa, kg/m2 23.7  1.0 22.9  0.7 .501
Caucasian, N 9 12 .217
Renal
Arterio-venous fistula, N 12
Dialysis durationa, mo 30  5
Diuresisa, mL/d 406  213
Dialysis adequacya,
Kt/V per wk
5.0  0.5
Comorbidity
Hypertension, % 75 8 .001
Blood pressure
Systolic blood pressurea,
mm Hg
134  5 131  6 .733
Diastolic blood pressurea,
mm Hg
86  3 82  3 .340
Laboratory results: screening
Hemoglobina, mmol/L 7.6  0.2 8.7  0.2 .001
Creatininea, mol/L 879  62 66  3 .0001
Urea nitrogena, mmol/L 16.3  1.5 4.7  0.4 .0001
Albumina, g/L 44  1 45  1 .756
Total carbon dioxidea,
mmol/L
26.8  1.0 27.8  0.8 .489
C-reactive proteina, mg/L 2.8  1.2 2.4  1.3 .711
Hemoglobin A1ca,
mmol/mol
33.1  0.9 36.1  0.9 .023
Sodiuma, mmol/L 140  1 141  1 .397
Potassiuma, mmol/L 4.6  0.2 3.6  0.1 .0001
Kt/V, clearancetime/volume (index).
a Data are presented as means  SEM.
b P values represent comparison between groups.
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Pilot study
A preceding pilot study was performed to estimate time to
steady-state concentrations of intact and total forms of GLP-1
and GIP during infusion. Two patients with ESRD were exam-
ined unblinded using the same setup as described above with the
exception that hormone infusionswere continued until 120min.
Each patient underwent 2 examination days: GLP-1 or GIP in-
fusion, respectively, with initial sitagliptin/placebo ingestion.
Total and intact plasma concentrations of GLP-1 or GIP were
measured at 17 individual time points. Using graphical evalua-
tion, steady state was estimated to occur at 60 min for both
GLP-1 and GIP. (Figures are attached as Supplemental Figure 1;
only results from the main study are presented below.)
Results
GLP-1
Fasting concentrations
Fasting concentrations of intact GLP-1 (7.1  0.7
pmol/L vs. 0.8 0.2 pmol/L; P .0001) and total GLP-1
(12.6 1.2 pmol/L vs. 6.5 0.8 pmol/L; P .001) were
higher in patients with ESRD than in
controls. Calculated fasting concen-
trations of the GLP-1 metabolite did
not differ between groups (5.5 1.0
pmol/L vs. 5.7  0.8 pmol/L; P 
.811).
Intact GLP-1 (GLP-1(7–36) amide)
MCR of intact GLP-1 was re-
duced in patients with ESRD com-
pared with controls on both exami-
nation days with GLP-1 infusion
(P .033), while T1/2 was similar in
the two groups (P .383). Baseline-
corrected AUC was comparable be-
tween groups at the placeboday (P
.536), but significantly increased in
theESRDgroup followingGLP-1 in-
fusion with sitagliptin (P  .019).
Metabolite GLP-1 (GLP-1(9–36)
amide)
MCR of the GLP-1 metabolite
was significantly reduced in patients
with ESRD on both examination
days (P  .007). T1/2 was increased
in patients with ESRD compared
with controls, insignificantly at the
placebo day (P  .121) and signifi-
cantly after sitagliptin ingestion (P
.020). AUC was significantly in-
creased in the ESRD group at both
examination days (P .018) andVd
was comparable between groups (P  .509).
Efficacy of DPP-4 inhibition
Use of sitagliptin significantly increased T1/2 and re-
duced MCR of intact GLP-1 in both groups (P  .013),
whereas T1/2 andMCRof theGLP-1metabolite remained
statistically unaltered by DPP-4 inhibition (P  .255).
Curves and pharmacokinetic data are presented in Figure
1 and Table 2.
GIP
Due to previously described interference in the assay
used for intact GIP analysis (3), baseline-subtracted GIP
responseswereused for evaluationof thepharmacokinetic
parameters.
Fasting concentrations
Fasting concentrations of intact GIP (34.1  2.3
pmol/L vs. 19.7  1.8 pmol/L; P  .001) and total GIP
(15.2 2.4 pmol/L vs. 1.7 0.4 pmol/L; P .001) were
Figure 1. Plasma total glucagon-like peptide-1 (GLP-1) (A and D), intact GLP-1 (B and E), and
GLP-1 metabolite (C and F) measurements during GLP-1 infusion with dipeptidyl peptidase 4
(DPP-4) inhibition (black curves) and without DPP-4 inhibition (red curves) in patients with ESRD
(A–C) and control subjects (D–F). The gray bars indicate the time period for infusion (0–60 min).
Data are mean  SEM.
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increased in patients with ESRD compared with controls.
Amean difference of 1.4 4.1 pmol/L between groups of
the calculated fasting concentrations of GIP metabolites
did not differ significantly (P  .738).
Intact GIP (GIP(1–42))
MCR of intact GIP was reduced and AUC was in-
creased in patients with ESRD compared with controls;
significantly at the placebo day (P  .009) and insignifi-
cantly after sitagliptin ingestion (P  .098). T1/2 and Vd
were similar in the two groups at both examination days
(P  .126).
Metabolite GIP (GIP(3–42))
T1/2, MCR, and Vd of the GIP metabolite were com-
parable between groups duringGIP infusionwith sitaglip-
tinandplacebo, respectively (P .097),whereasAUCwas
increased in theESRDgroupat theplaceboday (P .040).
Efficacy of DPP-4 inhibition
Sitagliptin administration increased T1/2 and reduced
MCR of intact GIP in both groups, although only MCR
was changed with statistical significance (P  .032).
Curves and pharmacokinetic data are presented in Figure
2 and Table 2.
Plasma glucose
No difference in fasting plasma glucose was observed
between patients with ESRD and controls (5.1  0.1
mmol/L vs. 5.2  0.1 mmol/L; P  .476). Responses fol-
lowing GLP-1 and GIP infusion, respectively, with or
without DPP-4 inhibition, did not differ between groups
(P .186). The glucose-lowering effect of GLP-1 andGIP
infusion, respectively, was more pronounced during
DPP-4 inhibition, although it did not reach statistical sig-
nificance (P  .107) (Figure 3).
Insulin and glucagon
Patientswith ESRDand controls exhibited comparable
fasting concentrations of insulin (45.1  3.8 pmol/L vs.
46.5  8.6 mmol/L; P  .879), whereas fasting concen-
trations of glucagon were elevated in the ESRD group
Table 2. Pharmacokinetic Parameters for GLP-1 and GIP
Parameter
GLP-1  Sitagliptin GLP-1  Placebo
ESRD
Mean (95% CI)
Control
Mean (95% CI)
P
Value
ESRD
Mean (95% CI)
Control
Mean (95% CI)
P
Value
Intact GLP-1 (GLP-1(7–36
amide)
T[½] (min) 4.66 (3.84–5.92) 4.07 (3.36–5.18) .383 2.47 (1.96–3.36)
a 2.53 (2.03–3.36)c .899
AUC (min  pmol/L) 867 (645–1089) 578 (459–697) .019 351 (186–516)a 301 (241–361)d .536
MCR (mL/kg/min) 36.7 (24.6–48.8) 50.5 (44.7–56.3) .033 70.5 (60.1–80.8)b 105.6 (83.1–128.2)d .005
Vd (L/kg) 0.25 (0.17–0.33) 0.30 (0.26–0.33) .271 0.25 (0.21–0.29) 0.39 (0.30–0.47) .004
Metabolite GLP-1
(GLP-1(9–36)
amide)
T[½] (min) 7.83 (5.28–15.11) 3.26 (2.29–5.65) .020 5.51 (3.99–8.91) 3.50 (2.53–5.70) .121
AUC (min  pmol/L) 1804 (1416–2191) 926 (468–1385) .004 2110 (1782–2439) 1430 (944–1916) .018
MCR (mL/kg/min) 17.5 (13.7–21.3) 35.3 (23.2–47.4) .007 13.7 (12.0–15.3) 26.7 (19.2–34.2) .002
Vd (L/kg) 0.20 (0.16–0.24) 0.17 (0.11–0.22) .509 0.11 (0.10–0.12) 0.13 (0.10–0.17) .852
Intact GIP (GIP(1–42))
T[½] (min) 8.66 (5.01–31.91) 6.30 (4.08–13.80) .477 4.47 (2.86–10.21) 3.35 (1.85–18.12) .594
AUC (min  pmol/L) 2444 (1766–3122) 1766 (1190–2341) .107 1523 (1097–1949)a 670 (369–971)c .001
MCR (mL/kg/min) 31.8 (20.8–42.7) 42.6 (32.5–56.6) .098 49.9 (34.4–67.0)a 99.1 (67.7–136.5)c .009
Vd (L/kg) 0.40 (0.26–0.53) 0.39 (0.30–0.51) .921 0.32 (0.22–0.43) 0.48 (0.33–0.66) .126
Metabolite GIP
(GIP(3–42))
T[½] (min) 15.34 (13.26–18.18) 10.03 (8.00–13.43) .311 22.22 (16.18–35.46)
a 15.77 (12.71–20.78) .447
AUC (min  pmol/L) 1667 (860–2473) 787 (57–1518) .089 3689 (2641–4737)b 2377 (1548–3206)d .040
MCR (mL/kg/min) 27.6 (22.0–33.2) 36.2 (26.4–45.9) .097 21.6 (11.5–31.7)b 36.7 (16.6–56.8)c .163
Vd (L/kg) 0.61 (0.49–0.73) 0.52 (0.38–0.66) .948 0.69 (0.37–1.02) 0.83 (0.38–1.29) .346
Vd, volume of distribution.
Listed P values represent comparison between groups.
Footnotes represent significance levels from within-group comparisons.
a ESRD during GLP-1/GIP infusion with sitagliptin vs. GLP-1/GIP infusion with placebo, P  .05.
b ESRD during GLP-1/GIP infusion with sitagliptin vs. GLP-1/GIP infusion with placebo, P  .001.
c Controls during GLP-1/GIP infusion with sitagliptin vs. GLP-1/GIP infusion with placebo, P  .05.
d Controls during GLP-1/GIP infusion with sitagliptin vs. GLP-1/GIP infusion with placebo, P  .001.
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(25.2  2.4 pmol/L vs. 6.7  0.6 mmol/L; P  .0001).
Baseline-corrected responses of insulin and glucagonwere
comparable between groups on all examination days (P
.553 and P  .300, respectively), with the exception that
only the control group demonstrated a significant sup-
pression of glucagon during GLP-1 infusion with sitaglip-
tin (P  .040). The baseline-corrected insulin and gluca-
gon responses were unaltered by pretreatment with
sitagliptin compared with placebo in both groups (P 
.481 and P  .102, respectively) (Figure 4).
Discussion
In the present study we demonstrate that non-diabetic pa-
tients with ESRD are characterized by A) preserved, al-
though reduced degradation of GLP-1(7–36) amide and
GIP(1–42), indicating a conserved function of DPP-4 and
other peptidases involved in the truncation of intact in-
cretin hormones; B) delayed, but relatively preserved
eliminationof theN-terminally trun-
cated metabolites GLP-1(9–36)
amide and GIP(3–42), pointing to
the importance of concurrent nonre-
nal elimination of these; and C) sig-
nificantly increased fasting concen-
trations of intact GLP-1 and GIP.
The present study examined pa-
tients with chronic dialysis-depen-
dent ESRD, ie, patients without or
with only negligible renal function.
The kidneys of patients with chronic
ESRD consist of fibrotic tissue and
very few, if any, functioning cells.
Consequently, renal endocrine, exo-
crine, and tubular functions, clear-
ance, and the ability to concentrate
urine are abolished, and the renal
blood flow is severely reduced or
nonexistent (27–29). Eight of 12 pa-
tients in our study had no diuresis,
indicating total cessation of any re-
nal functions. Four patients had pre-
served diuresis in the range of 300–
2300 mL/d. Urine from a patient
with ESRD contains small amounts
of waste products and electrolytes
due to renal clearance close to 0 mL/
min (30). Accordingly, the pharma-
cokinetic data did not differ between
our ESRD subjects with andwithout
diuresis (P  .152; MCR values for
each subgroup at the placebo-days
are presented as Supplemental Table 2). Thus, the present
study should enable us to elaborate on the role of the
kidneys in degradation and elimination of intact and me-
tabolite forms of GLP-1 and GIP. Sitagliptin-induced
DPP-4 inhibition was included in the design in order to
further visualize the effect of the kidneys on the elimina-
tion of the incretin hormones after reduction of the en-
dogenous DPP-4-mediated degradation. The placebo day
allowed us to estimate the endogenous DPP-4 activity. As
expected, DPP-4 inhibition resulted in increased concen-
trations of intact hormone levels and, hence, reduced con-
centrations of the metabolites compared with placebo
(Figure 1, B–F and Figure 2, B–F), resulting in a signifi-
cantly reducedMCR of intact GLP-1 and GIP by approx-
imately 50% in both groups (P  .014). Thus, our data
suggest preserved DPP-4-mediated degradation of intact
GLP-1 andGIP in patientswith ESRD.Toour knowledge,
only one study has previously examined degradation and
elimination of intact GLP-1 andGIP in patients with renal
Figure 2. Plasma total GIP (A and D), intact GIP (B and E), and GIP metabolite (C and F)
measurements, illustrated as baseline-subtracted values during GIP infusion with dipeptidyl
peptidase 4 (DPP-4) inhibition (green curves) and without DPP-4 inhibition (purple curves) in
patients with ESRD (A–C) and control subjects (D–F). The gray bars indicate the time period for
infusion (0–60 min). Data are mean  SEM.
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impairment: Meier et al (10) enrolled 10 patients with
moderate renal impairment (creatinine clearance 46 24
mL/min) and infused GLP-1 and GIP over 30 min (ie, not
sufficiently for obtaining steady state according to our
pilot study (Supplemental Figure 1)). T1/2 of intact GLP-1
has previously been reported to be approximately 2min in
healthy individuals (10, 26), and Meier et al (10) found
this to be insignificantly increased in patients with mod-
erate renal impairment (3.4 min; P .13). The same pat-
tern was observed with regard to intact GIP, andMCR of
intact GLP-1 and GIP was insignificantly reduced (3, 10).
These results are in accordance with our findings, al-
though the differences were more pronounced in patients
with severe renal impairment; MCR of intact GLP-1 and
GIPwas reduced in theESRDgroupbyapproximately one
third compared with the control group and AUCs of both
intact hormones were increased. This suggests a contrib-
utory role of the kidneys in degradation of intact GLP-1
and GIP causing reduced, although partially preserved
degradation in patients with ESRD. T1/2 of intact GIPwas
insignificantly increased in the ESRD group, whereas T1/2
of intact GLP-1 was almost identical in the two groups.
Previous studies on pigswith normal kidney function have
demonstrated a renal extraction of approximately 70%of
intact GLP-1 and 25% of intact GIP with glomerular fil-
tration, proteolysis, and perhaps peritubular reuptake
being involved (9, 14).With the kidneys receiving approx-
imately 25% of the cardiac output, approximately 10–
20% of the clearance of intact incretin hormones can be
explained by this mechanism. In addition to DPP-4-
mediated degradation of intact in-
cretinhormones, extractionhasbeen
shown to occur in the liver (GLP-1
and GIP) (9, 14), extremities, and
lungs (GLP-1) (14). These nonrenal
degradation mechanisms probably
explain the only slightly reduced
ability to eliminate intact GLP-1 and
GIP in the ESRD group as observed
both with and without DPP-4 inhi-
bition. In summary, our results sug-
gest that nonrenal, non-DPP-4-me-
diated degradation constitutes a
possible compensatory mechanism
for the maintenance of approxi-
mately two thirds of normal degra-
dation and elimination of the intact
incretin hormones.
As with intact incretin hormones,
few studies have examined elimina-
tion and degradation of the metabo-
lites of GLP-1 and GIP in the setting
of renal impairment. Most of these
studies used assays unable to distinguish between intact
hormones and N-terminally truncated metabolites (10–
12, 15–17).Nevertheless, the kidneys have been suggested
to be crucial for the elimination of “total GLP-1” (10–12)
and “total GIP” (10, 15–17). Meier et al (10) measured
intact and metabolite levels separately and concluded, in
accordance with previous studies, that the kidneys are es-
sential for elimination of the metabolites of GLP-1 and
GIP. Nonetheless, elimination and degradation of the N-
terminally truncated metabolites have never been exam-
ined in patients with ESRD. The present study clearly re-
veals involvement of the kidneys in elimination and
degradation of the metabolites of GLP-1 and GIP; MCR
values were reduced by 40–50% in the ESRD group com-
pared with the control group during the placebo days and
AUCs were increased. It is, however, surprising that non-
renal degradation and elimination can partly compensate
for the extinct or severely reduced kidney function, which
is in contrast to previous studies (10–12, 15–17). The in-
significantly increased T1/2 of bothmetabolites in patients
with ESRDand the comparable fasting concentrations be-
tween groups strengthen this conclusion. Increased activ-
ity of NEPs may constitute a possible explanation. NEP
24.11 (neprilysin, CD10) is themost commonly occurring
andwell studied of these enzymes and has been detected in
several tissues and organs. It cleaves GLP-1 and GIP at
various sites, resulting in metabolites different from the
DPP-4-induced cleavage products (i.e. metabolites that
are not caught in the assaymeasuring totalGLP-1 andGIP
Figure 3. Plasma glucose responses during GLP-1 infusion (A and C) and GIP infusion (B and D)
with dipeptidyl peptidase 4 (DPP-4) inhibition (black and green curves) and without DPP-4
inhibition (red and blue curves) in patients with ESRD (A and B) and control subjects (C and D).
The gray bars indicate the time period for infusion (0–60 min). Data are mean  SEM.
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in our study) (6, 7, 13). NEP 24.11 degrades GLP-1 both
in vivo and in vitro (6, 7, 31). GIP is degradedmore slowly
byNEP 24.11 in vitro and its relevance inGIPmetabolism
in vivo has not yet been established (6, 7, 32). Organ ex-
traction constitutes another possible compensatorymech-
anism for degradation and elimination of the truncated
metabolites. A significant extraction from the fibrotic kid-
neys in patients with ESRD is unlikely (27–30) and pre-
vious studiesmeasuring total levels ofGLP-1 (14) andGIP
(33)have suggested that the liverdoesnotplayamajor role
in the elimination and degradation of the metabolites of
the incretin hormones. Both N- and C-terminal degrada-
tion of the incretin hormones occurs in peripheral tissues
(9, 14), thus constituting a possible
nonrenal compensatory elimination
site. Extraction from other organs
cannot be excluded and additional
studies examining in vivo and in
vitro organ-specific extraction as
well as NEP activity in patients with
varying degrees of renal impairment
are warranted.
The presence of significantly in-
creased fasting concentrations of in-
tact GLP-1 and GIP in patients with
ESRD represents novel findings.
Causes and/or consequences cannot
be extracted from the present study,
but it correlates well with the results
of a previous study in which patients
with ESRD exhibited exaggerated
postprandial responses of total
GLP-1 compared with healthy con-
trol subjects (19). Furthermore, our
data confirm the presence of severely
increased fasting concentrations of
glucagon in nondiabetic patients
with ESRD (18, 19), the underlying
pathophysiology of which is yet un-
charted. Fasting glucose and insulin
concentrations were comparable
and within normal levels in both
groups, suggesting preserved insulin
sensitivity. Even though insulin re-
sistance is common in patients with
ESRD (34), this finding is in linewith
previous studies by our group (18,
19). The negligible responses of in-
sulin and glucagon and the corre-
sponding, limited effects on plasma
glucose in thepresent studyare prob-
ably due to the normoglycemic ex-
perimental conditions, given that
neither GLP-1 nor GIP induce major changes in islet se-
cretion at normoglycemia. Future studies using clamp
techniques during GLP-1 and GIP infusion, respectively
are warranted for a thorough characterization of the pan-
creatic effects of incretin hormones in patientswithESRD.
Safety and efficacy of incretin-based therapies in patients
with impaired kidney function, including patients with
ESRD (35), has been investigated in randomized con-
trolled trials. Although our study was designed solely for
pharmacokinetic analyses, our results suggest a main-
tained efficacy of DPP-4 in a severe uremic environment,
whichwould be a prerequisite for use of DPP-4 inhibitors.
Figure 4. Plasma insulin (A–D) and glucagon (E–H) responses during GLP-1 infusion (A, C, E,
and G) and GIP infusion (B, D, F, and H) with dipeptidyl peptidase 4 (DPP-4) inhibition (black and
green curves) and without DPP-4 inhibition (red and blue curves) in patients with ESRD (A, B, E,
and F) and control subjects (C, D, G, and H). The gray bars indicate the time period for infusion
(0–60 min). Data are mean  SEM.
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Furthermore, our data may suggest the need for dose re-
duction of GLP-1 receptor analogs (in case these are de-
graded and eliminated with similar kinetics as human
GLP-1) in diabetic patients with ESRD due to reduced
MCR of intact and metabolite GLP-1. The delayed me-
tabolism of the GLP-1 metabolite in patients with ESRD
may have beneficial cardiovascular effects (36), although
additional studies are needed to elucidate this.
Our study has limitations. We were unable to perform
a regular prestudy power analysis because no historical
data on the pharmacokinetics of GLP-1 and GIP in pa-
tients with severely reduced kidney function exists. Thus,
type 2 errors cannot be precluded, although the number of
examined patients is above that in similar pharmacoki-
netic human studies. Also, the patients with ESRD com-
prised a heterogeneous group with different underlying
renal diseases and ethnicity. Tominimize confounding ef-
fects of this we matched patients and controls on age, sex,
and BMI and gave preference to nondiabetic patients with
ESRD with little comorbidity. We assess these minor dif-
ferences to be of little significance for the pharmacokinetic
evaluation of incretin hormones in patients with ESRD.
The study design represents a nonphysiological setting
and first-pass metabolism from the portal system is not
achieved following iv infusion. This may affect the phar-
macokinetic results; however, previous animal studies
have not identified the liver as a major site of degradation
and elimination of GLP-1 and GIP (except for hepatic
DPP-4 activity). Furthermore, study conditionswere iden-
tical in all participants, thus allowing comparisonbetween
groups. Blood samples were drawn from a peripheral vein
in control subjects whereas an arterio-venous fistula was
used in the patients with ESRD. Tominimize possible dif-
ferences, a heating padwas used to “arterialize” the blood
in the control group. Finally, we did not measure DPP-4
activity or plasma concentrations of sitagliptin. Neverthe-
less, the intention of the design was, qualitatively, to ex-
amine the efficacy of DPP-4 in a uremic environment and
to elucidate DPP-4-independent elimination and degrada-
tion mechanisms further. These aims were achieved.
In conclusion, our results suggest that degradation and
elimination of intact and N-terminally truncated metab-
olites of GLP-1 and GIP, respectively, are delayed, but
relatively preserved, despite an extinct or severely reduced
kidney function. DPP-4-mediated degradation of the in-
tact hormones seems unaffected by severe uremiawhereas
nonrenal degradation and elimination of the incretin me-
tabolites—perhaps constituted by NEPs or yet unknown
factors—seem to exist.
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